transgene announcement, page-27

Lil & all,
The trading action on Transgene after this news is just incredible. More than 10% (close to 1.1M) of the 10m (45%) available shares in the market changed hand today. The highest ever volume traded of this stock... dropping about 15%.

It looks like Transgene will get $10 USD none-refundable for now. I think Virax's sub-licensing payment would be around 10% of that..... What surprised me is the 700m instead of 400m Euros as rumor for a completed sell off to Novartis when option is exercised..

Well, at least my blood won't boil knowing that Transgene has to work hard for this money.. No more easy money being a middleman and cutting large commission on Virax's Co-X-Gene.

No doubt, some who has bought in VHL for transgene deal may be disappointed and sell out tomorrow. I was accumulated upto 10c, hopefully this would give a good entry for new shareholders and me another chance to accumulate below 10c again.

You are right, this deal is another stamp on Virax's Co-X-Gene technology.... and that give a wonderful winning chance for VIR-201..

Should Transgene launch an all scrips take over of Virax, it only cost them about 1.9 million shares.

The question is...would we happy to swap VHL to TNG at the 1:100 ratio ?. No way !!!!


++++++++++++++++++++++++++++++++++++++++++++++++
The biotechnology company has been chosen to give an option to license exclusive worldwide rights TG4010 the Swiss pharmaceutical group Novartis. In return for this license option global biopharmaceutical company will receive a non-refundable $ 10 million and will then receive payments up to a total of 700 million euros, depending on the option exercise by Novartis and the milestones of development, regulatory approvals and thresholds of global turnover.

During the conference call this morning, Philipe Archinard justified in clear decisions: "We keep a degree of control greater than if we had handed over to the partner. This allows us to maintain operational pressure on the timetable we set ourselves, "said the officer.

Contrary to what would have happened if tranfer of rights, Transgene will fund and maintain control of the first part (Phase IIb) to the next stage of clinical development of product. The latter consist of a clinical phase IIb / III world.

But "in financial terms, our cash position is comfortable. The estimated costs for this part IIb that we will fund its own 15 million is reasonable, "said Philippe Archinard. The officer said here that Transgene has the support of its shareholder, the Mrieux family, which believes in the product.
++++++++++++++++++++++++++++++++++++++++++++++++++